Literature DB >> 12167681

Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.

Allison Brashear1, Mark F Gordon, Elie Elovic, V Daniel Kassicieh, Christina Marciniak, Mai Do, Chia-Ho Lee, Stephen Jenkins, Catherine Turkel.   

Abstract

BACKGROUND: Spasticity is a disabling complication of stroke, and it is uncertain whether intramuscular injections of botulinum toxin type A reduce disability in persons with spasticity of the wrist and fingers after a stroke.
METHODS: We performed a randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of one-time injections of botulinum toxin A (200 to 240 units) in 126 subjects with increased flexor tone in the wrist and fingers after a stroke. The primary outcome measure was self-reported disability in four areas: personal hygiene, dressing, pain, and limb position (on a four-point scale ranging from no disability to severe disability) at six weeks; at base line, each subject selected one of these areas in which there was moderate-to-severe disability as the principal target of treatment.
RESULTS: Subjects who received botulinum toxin A had greater improvement in flexor tone in the wrist and fingers at all follow-up visits through 12 weeks than did subjects who received placebo (P<0.001 for all comparisons). Subjects treated with botulinum toxin A had greater improvement in the principal target of treatment at weeks 4, 6, 8, and 12 (P<0.001, P<0.001, P=0.03, and P=0.02, respectively); at week 6, 40 of the 64 subjects in the botulinum-toxin group (62 percent), as compared with 17 of the 62 in the placebo group (27 percent), reported improvement of at least one point on the Disability Assessment Scale in the principal target of treatment (P<0.001). There were no major adverse events associated with injection of botulinum toxin A.
CONCLUSIONS: Intramuscular injections of botulinum toxin A reduce spasticity of the wrist and finger muscles and associated disability in patients who have had a stroke. Copyright 2002 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167681     DOI: 10.1056/NEJMoa011892

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  100 in total

1.  Methods for a randomized trial of weight-supported treadmill training versus conventional training for walking during inpatient rehabilitation after incomplete traumatic spinal cord injury.

Authors:  Bruce H Dobkin; David Apple; Hugues Barbeau; Michele Basso; Andrea Behrman; Dan Deforge; John Ditunno; Gary Dudley; Robert Elashoff; Lisa Fugate; Susan Harkema; Michael Saulino; Michael Scott
Journal:  Neurorehabil Neural Repair       Date:  2003-09       Impact factor: 3.919

Review 2.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 3.  Strategies for stroke rehabilitation.

Authors:  Bruce H Dobkin
Journal:  Lancet Neurol       Date:  2004-09       Impact factor: 44.182

4.  [Intrathecal baclofen therapy in ambulatory patients with spastic hemiparesis following stroke. Short report of two cases].

Authors:  S Kästner
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

5.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

6.  High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis.

Authors:  Alessio Baricich; Elisa Grana; Stefano Carda; Andrea Santamato; Carlo Cisari; Marco Invernizzi
Journal:  J Neural Transm (Vienna)       Date:  2015-02-28       Impact factor: 3.575

7.  Extra- and intramuscular nerve supply of the muscles of the anterior antebrachial compartment: applications for selective neurotomy and for botulinum toxin injection.

Authors:  D Lepage; B Parratte; L Tatu; F Vuiller; G Monnier
Journal:  Surg Radiol Anat       Date:  2005-11-25       Impact factor: 1.246

8.  Does reducing spasticity translate into functional benefit? An exploratory meta-analysis.

Authors:  H P Francis; D T Wade; L Turner-Stokes; R S Kingswell; C S Dott; E A Coxon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 9.  Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.

Authors:  Andrea Santamato; Francesco Panza
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

10.  The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.

Authors:  A M O Bakheit; N V Fedorova; A A Skoromets; S L Timerbaeva; B B Bhakta; L Coxon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.